FORM 4 Check this box if no longer subject to Section 16. Form 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours	
response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)																
Name and Address of Reporting Person – Shenouda Maged				2. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Director 10% Owner						
C/O RELMADA TH	(First) IERAPEUTICS		Middle) RD AVENUE,	3. Date of Earliest Transaction (Month/Day/Year) 01/22/2021					X Officer (give title below) Other (specify below) CFO							
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year) 01/27/2021						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3) Date			Execution Date, if any		, ,		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		l (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership Form: of Indirect Beneficia	Beneficial		
				(Mon	th/Day/Yea	r) Code	e	v	Amount	(A) or (D)	Price				Direct (D) or Indirect (I) (Instr. 4)	
Common Stock 01/22/20			01/22/202	21 M 4,000 A \$ 3.24 6,228			5,228 D			D						
Reminder: Report on a see	eparate line for each	class of securities be	,	directly or indi		curities Acq	req	uire	d to respo	ond unless	the for	ction of information contai m displays a currently vali			SEC	1474 (9-02)
				(e.g	., puts, cal	ls, warrants	, option	s, cor	nvertible s	ecurities)			•			1
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	if Code Sec (Instr. 8) Sec		Number of Derivative curities Acquired (A) or sposed of (D) astr. 3, 4, and 5)					Securi	e and Amount of Underlying ties 3 and 4)	Derivative Security	Securities Beneficially	Ownership Form of I Derivative	Beneficial Ownership	
	Security			Code	V	(A)	(D)		Date Exercisabl	Expiration Date	Title	Amount or Number of Shares		Owned Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect	(Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Shenouda Maged C/O RELMADA THERAPEUTICS, INC. 880 THIRD AVENUE, 12TH FLOOR NEW YORK, NY 10022			CFO			

Signatures

/s/ Maged Shenouda	01/27/2021
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

This Form 4/A is being filed solely to correct a typographical error in the price per share of the security on the original Form 4 from "\$324" to "\$3.24" No other changes have been made to the original Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.